-
Views
-
Cite
Cite
V Oleinikov, E Dushina, Y Barmenkova, N Burko, O Kvasova, P4645
Nephroprotective effect of lipid-lowering therapy in patients after STEMI, European Heart Journal, Volume 39, Issue suppl_1, August 2018, ehy563.P4645, https://doi.org/10.1093/eurheartj/ehy563.P4645Close - Share Icon Share
Extract
Aim: To evaluate the effect of long-term statin therapy on the renal functional capacity in patients with ST-segment elevation myocardial infarction (STEMI).
Methods: Totaly 100 patients with STEMI were examined at the age of 52 (45.5, 59) years without signs of chronic kidney disease above C3 stage (creatinine clearance less than 30 mL/min). All patients were taken atorvastatin after STEMI for 48 weeks. On 7th day of STEMI, and every 24 weeks the creatinine level was determined using the Olympus AU400 analyzer, glomerular filtration rate (GFR) by CKD-EPI (Chronic Kidney Desease Epidemiology Collaboration, 2009) was calculated. Evaluation of the lipid-lowering therapy effectiveness was based on the level of LDL-cholesterol values less than 1.8 mmol/L and/or a decrease by 50% from the baseline. The patients were divided into groups by the 48th week of treatment: the “E” effective lipid-lowering therapy group comprised 51 people who had reached the LDL target, 49 patients with non-effective treatment of “NT” included patients who did not meet the target LDL level. The groups were matched by gender, age, anthropometric data.
